Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Astellas’ Gastric Cancer Drug Vyloy Now Available in Japan
June 13, 2024
- Ono Completes Acquisition of Deciphera
June 13, 2024
- En Route to 2030 Target, Shionogi to Carve Out New Biz in Areas with High Medical Needs
June 12, 2024
- Otsuka Resolved to Log 2.5 Trillion Yen in FY2028 by Offsetting Patent Cliffs with Novel Drugs
June 12, 2024
- Kyowa Kirin to Build Biologics Manufacturing Site in North Carolina
June 12, 2024
- Maruho Launches Mitchga 30 mg Vial Version in Japan
June 12, 2024
- US FDA Snubs Mitsubishi Tanabe’s Parkinson’s Drug
June 12, 2024
- Takeda Rebuts ISS’ Advice to Vote against Re-Election of CEO Weber
June 11, 2024
- Susana Murteira Tapped as Amgen Japan President
June 11, 2024
- Alecensa Snags EU OK for Adjuvant Setting of ALK-Positive NSCLC
June 11, 2024
- Japan Ethical Drug Sales Up 7.3% in April: Crecon
June 11, 2024
- Keytruda Tops Japan Drug Sales Ranking for 8 Months on End: Encise
June 11, 2024
- Takeda Rolls Out Obizur for Acquired Hemophilia A in Japan
June 11, 2024
- Kissei Grants Korean Rights for GnRH Antagonist Linzagolix to JW
June 11, 2024
- Leqembi’s Monthly IV Dosing Accepted for FDA Review: Eisai
June 11, 2024
- Moderna Files Updated Spikevax for JN.1 Strain in Japan
June 11, 2024
- Rohto Bags Majority Stake in Austria Pharma to Boost European Biz
June 10, 2024
- Towa Files NDA for Rivastigmine Twice Weekly Transdermal Patch in Japan
June 10, 2024
- Novavax COVID Vaccine to Be Adapted to JN.1 Strain: Takeda
June 10, 2024
- Shionogi Gets Option Rights to Cilcare’s Hearing Loss Assets
June 10, 2024
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…